We are working to advance a growing pipeline of oncology therapies and diagnostics with an intense focus on targeted therapies and improving our own immune system, allowing patients to live longer, healthier lives.
We have hundreds of compounds in our Intellectual Property Portfolio. Currently one lead compound is in IND-enabling tox studies and ready immediately thereafter for clinical trials. This small molecule, Ax-101, is an immune system modulatory agent, proven safe and effective in a previous First-in-Human (FIH) trial. Orphan Drug Status has already been awarded to Ax-101 for lymphoma and metastatic melanoma.
The first proven effective glutamine transport inhibitor (GTI) in in-vivo studies in multiple cancers, V-9302, demonstrated considerable antitumor activity against cancer cells, while simultaneously strengthening the immune system. We have since identified additional compounds that have performed considerably better than V-9302 and are moving rapidly to lead nomination.
Additionally, a GTI Companion Diagnostic (CDx) that identifies cancer and patients that will respond to our GTI therapy.
